Focused Pharmacogenomics Panel
Test in Focus
Mayo Clinic Laboratories’ updated focused pharmacogenomics panel uses real-time, PCR testing for targeted genotyping of 10 genes with known associations to medications used to treat a variety of disorders across a spectrum of specialities. In this “A Test in Focus” episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how this innovative assay helps guide providers on choosing the best treatment option for their patients.
“The goal of this panel would be that it should be useful for patients that are either on many different medications or patients where the differential diagnosis is still rather broad, where it's difficult to decide which medication to put the patient on,” Dr. Moyer says “Because these drugs metabolize so many different medications, hopefully this is a panel that, once the patient has it ordered, it can be reused again and again, throughout their care, no matter what specialty they're seeing.”
By including both genotype and phenotype evaluation of those genes with a high level of evidence for metabolic associations to medications, the test enables detailed insights on patients’ genetic dispositions, Dr. Moyer says. “We tried to be really careful and cognizant about making sure that we include all of the alleles that are relevant for various patient populations throughout the world. And I think that makes our tests something that should be useful for years to come.”
Listen to learn more about how our focused pharmacogenomics panel can help guide treatment selection and improve treatment outcomes for patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Submit only 1 of the following specimens:
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.